LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Amgen Inc

Amgen Inc

Chiusa

SettoreSettore sanitario

345.56 2.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

338.35

Massimo

348.29

Metriche Chiave
By Trading Economics
Entrata	486M 1.8B
Vendite	-1.3B 8.6B
P/E Media del settore	22.888 49.888
EPS	5.15
Rendimento da dividendi	2.87
Margine di Profitto	21.107
Dipendenti	31,500
EBITDA	-2.3B 2.7B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.83% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.87% 2.38%
Utili prossimi	4 ago 2026
Prossima data del Dividendo	5 giu 2026
Prossima data del' Ex Dividendo	21 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-5.7B 178B
Apertura precedente	343.5
Chiusura precedente	345.56

Notizie sul Sentiment di mercato

By Acuity

43%

57%

139 / 344 Classifica in Healthcare

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 20:16 UTC

Utili

Amgen Posts Higher 1Q Profit, Revenue

6 apr 2026, 17:09 UTC

I principali Market Mover

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 feb 2026, 21:49 UTC

Utili

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 gen 2026, 15:14 UTC

Acquisizioni, Fusioni, Takeovers

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 nov 2025, 21:55 UTC

I principali Market Mover

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 apr 2026, 20:01 UTC

Utili

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen 1Q Adj EPS $5.15 >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen 1Q Rev $8.62B >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen 1Q Net $1.82B >AMGN

30 apr 2026, 20:01 UTC

Utili

Amgen 1Q EPS $3.34 >AMGN

1 apr 2026, 20:07 UTC

Acquisizioni, Fusioni, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 feb 2026, 19:56 UTC

Discorsi di Mercato

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Adj EPS $5.29 >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Net $1.33B >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Rev $9.9B >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 feb 2026, 21:01 UTC

Utili

Amgen 4Q EPS $2.45 >AMGN

28 gen 2026, 17:47 UTC

Utili

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 gen 2026, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 gen 2026, 14:01 UTC

Acquisizioni, Fusioni, Takeovers

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 gen 2026, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.83% in crescita

Previsioni per 12 mesi

Media 361.33 USD 6.83%

Alto 427 USD

Basso 300 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amgen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

24 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 24 che hanno fornito valutazioni azionarie a Amgen Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

139 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.